Header Logo

Robert S Mannel

TitleProv,Asoc Vc Cancer Programs
InstitutionUniversity of Oklahoma Health Sciences Center
DepartmentStephenson Cancer Center
AddressSOCC 6043
800 NE 10th St
Oklahoma City OK 73104
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    P30CA225520     (MANNEL, ROBERT S.)May 1, 2018 - Apr 30, 2028
    NIH
    Stephenson Cancer Center - Cancer Center Support Grant
    Role: Principal Investigator
    U10CA180798     (MANNEL, ROBERT S)Apr 24, 2014 - Feb 28, 2019
    NIH
    Lead Academic Participating Site for the Development and Conduct of NCTN Trials
    Role: Principal Investigator
    U10CA180868     (WOLMARK, NORMAN)Apr 17, 2014 - Feb 28, 2025
    NIH
    NRG Oncology Network Group Operations Center
    Role: Co-Principal Investigator
    P20CA097943     (MANNEL, ROBERT S)Sep 30, 2002 - Aug 31, 2008
    NIH
    Cancer Center Planning Grant (P20)
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. O'Dwyer PJ, Wolmark N, Hawkins DS, Schnall M, Dancey J, Blanke C, Mannel R, Galanis E, Le QT. Correlative Science in the Cooperative Group System-Re-Engineering for Success. J Clin Oncol. 2024 Sep 17; JCO2400527. PMID: 39288338.
      Citations:    Fields:    
    2. Landen CN, Buckanovich RJ, Sill MW, Mannel RS, Walker JL, DiSilvestro PA, Mathews CA, Mutch DG, Hernandez ML, Martin LP, Bishop E, Gill SE, Gordinier ME, Burger RA, Aghajanian C, Liu JF, Moore KN, Bookman MA. Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study. J Clin Oncol. 2024 Jul 20; 42(21):2537-2545. PMID: 38776484.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    3. Klopp AH, Enserro D, Powell M, Randall M, Schink JC, Mannel RS, Holman L, Bender D, Kushnir CL, Backes F, Zweizig SL, Waggoner S, Bradley KA, Lawrence LD, Hanjani P, Darus CJ, Small W, Cardenes HR, Feddock JM, Miller DS. Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial. J Clin Oncol. 2024 Jul 10; 42(20):2425-2435. PMID: 38662968.
      Citations: 1     Fields:    Translation:Humans
    4. Horowitz NS, Deng W, Peterson I, Mannel RS, Thompson S, Lokich E, Myers T, Hanjani P, O'Malley DM, Chung KY, Miller DS, Ueland FR, Dizon DS, Miller A, Mayadev JS, Leath CA, Monk BJ. Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279. J Clin Oncol. 2024 Apr 04; JCO2302235. PMID: 38574312.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    5. Zhang K, Abdoli N, Gilley P, Sadri Y, Chen X, Thai TC, Dockery L, Moore K, Mannel RS, Qiu Y. Developing a novel image marker to predict the clinical outcome of neoadjuvant chemotherapy (NACT) for ovarian cancer patients. Comput Biol Med. 2024 Apr; 172:108240. PMID: 38460312.
      Citations: 1     Fields:    Translation:Humans
    6. Abdoli N, Zhang K, Gilley P, Chen X, Sadri Y, Thai T, Dockery L, Moore K, Mannel R, Qiu Y. Evaluating the Effectiveness of 2D and 3D CT Image Features for Predicting Tumor Response to Chemotherapy. Bioengineering (Basel). 2023 Nov 20; 10(11). PMID: 38002458; PMCID: PMC10669238.
      Citations:    
    7. Zhang K, Abdoli N, Gilley P, Sadri Y, Chen X, Thai TC, Dockery L, Moore K, Mannel RS, Qiu Y. Developing a Novel Image Marker to Predict the Responses of Neoadjuvant Chemotherapy (NACT) for Ovarian Cancer Patients. ArXiv. 2023 Sep 13. PMID: 37744460; PMCID: PMC10516116.
      Citations:    
    8. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R. Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 2023 Sep 01; 41(25):4077-4083. PMID: 37643542.
      Citations: 4     Fields:    Translation:CTClinical Trials
    9. Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel R, Shahin MS, Cantuaria GH, Girda E, Mathews C, Kavecansky J, Leath CA, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O'Cearbhaill RE, Al Baghdadi T, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. N Engl J Med. 2023 03 27. PMID: 36972022.
      Citations: 95     Fields:    Translation:HumansCellsCTClinical Trials
    10. Unger JM, LeBlanc M, George S, Wolmark N, Curran WJ, O'Dwyer PJ, Schnall MD, Mannel RS, Mandrekar SJ, Gray RJ, Zhao F, Bah M, Vaidya R, Blanke CD. Population, Clinical, and Scientific Impact of National Cancer Institute's National Clinical Trials Network Treatment Studies. J Clin Oncol. 2023 Apr 10; 41(11):2020-2028. PMID: 36480773; PMCID: PMC10082246.
      Citations: 3     Fields:    Translation:Humans
    11. You B, Purdy C, Copeland LJ, Swisher EM, Bookman MA, Fleming G, Coleman R, Randall LM, Tewari KS, Monk BJ, Mannel RS, Walker JL, Cappuccini F, Cohn D, Muzaffar M, Mutch D, Wahner-Hendrickson A, Martin L, Colomban O, Burger RA. Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study. J Clin Oncol. 2022 Dec 01; 40(34):3965-3974. PMID: 36252167.
      Citations: 15     Fields:    Translation:Humans
    12. Van der Kolk WL, Van der Zee AGJ, Slomovitz BM, Baldwin PJW, Van Doorn HC, De Hullu JA, Van der Velden J, Gaarenstroom KN, Slangen BFM, Kjolhede P, Br?nnstr?m M, Vergote I, Holland CM, Coleman R, Van Dorst EBL, Van Driel WJ, Nunns D, Widschwendter M, Nugent D, DiSilvestro PA, Mannel RS, Tjiong MY, Boll D, Cibula D, Covens A, Provencher D, Runnebaum IB, Monk BJ, Zanagnolo V, Tamussino K, Oonk MHM, all GROINSS-V I and II participants. Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe. Gynecol Oncol. 2022 10; 167(1):3-10. PMID: 36085090.
      Citations: 2     Fields:    Translation:Humans
    13. Pitiyarachchi O, Friedlander M, Java JJ, Chan JK, Armstrong DK, Markman M, Herzog TJ, Monk BJ, Backes F, Secord AA, Bonebrake A, Rose PG, Tewari KS, Lentz SS, Geller MA, Copeland LJ, Mannel RS. What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (=10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer. Gynecol Oncol. 2022 09; 166(3):410-416. PMID: 35835612.
      Citations: 3     Fields:    Translation:Humans
    14. Copeland LJ, Brady MF, Burger RA, Rodgers WH, Huang HQ, Cella D, O'Malley DM, Street DG, Tewari KS, Bender DP, Morris RT, Lowery WJ, Miller DS, Dewdney SB, Spirtos NM, Lele SB, Guntupalli S, Ueland FR, Glaser GE, Mannel RS, DiSaia PJ. Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study. J Clin Oncol. 2022 Jun 27; JCO2200146. PMID: 35759733.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    15. Jackson CG, Moore KN, Cantrell L, Erickson BK, Duska LR, Richardson DL, Landrum LM, Holman LL, Walker JL, Mannel RS, Moxley KM, Queimado L, Cohoon A, Ding K, Dockery LE. A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium. Gynecol Oncol. 2022 07; 166(1):44-49. PMID: 35491267.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    16. Chen X, Wang X, Zhang K, Fung KM, Thai TC, Moore K, Mannel RS, Liu H, Zheng B, Qiu Y. Recent advances and clinical applications of deep learning in medical image analysis. Med Image Anal. 2022 07; 79:102444. PMID: 35472844.
      Citations: 115     Fields:    Translation:Humans
    17. Wenzel L, Osann K, McKinney C, Cella D, Fulci G, Scroggins MJ, Lankes HA, Wang V, Nephew KP, Maxwell GL, Mok SC, Conrads TP, Miller A, Mannel RS, Gray HJ, Hanjani P, Huh WK, Spirtos N, Leitao MM, Glaser G, Sharma SK, Santin AD, Sperduto P, Lele SB, Burger RA, Monk BJ, Birrer M. Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival. J Natl Cancer Inst. 2021 10 01; 113(10):1369-1378. PMID: 33729494.
      Citations: 6     Fields:    Translation:Humans
    18. Oonk MHM, Slomovitz B, Baldwin PJW, van Doorn HC, van der Velden J, de Hullu JA, Gaarenstroom KN, Slangen BFM, Vergote I, Brännström M, van Dorst EBL, van Driel WJ, Hermans RH, Nunns D, Widschwendter M, Nugent D, Holland CM, Sharma A, DiSilvestro PA, Mannel R, Boll D, Cibula D, Covens A, Provencher D, Runnebaum IB, Luesley D, Ellis P, Duncan TJ, Tjiong MY, Cruickshank DJ, Kjølhede P, Levenback CF, Bouda J, Kieser KE, Palle C, Spirtos NM, O'Malley DM, Leitao MM, Geller MA, Dhar K, Asher V, Tamussino K, Tobias DH, Borgfeldt C, Lea JS, Bailey J, Lood M, Eyjolfsdottir B, Attard-Montalto S, Tewari KS, Manchanda R, Jensen PT, Persson P, Van Le L, Putter H, de Bock GH, Monk BJ, Creutzberg CL, van der Zee AGJ. Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II. J Clin Oncol. 2021 11 10; 39(32):3623-3632. PMID: 34432481.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    19. Monk BJ, Coleman RL, Herzog TJ, Moore KN, O'Malley DM, Randall LM, Slomovitz BM, Eskander R, Pothuri B, Reese LL, Mannel RS, Copeland LJ. The GOG partners: A program for industry sponsored clinical trials in gynecologic oncology within the GOG foundation. Gynecol Oncol. 2021 07; 162(1):203-209. PMID: 33722417.
      Citations: 1     Fields:    Translation:Humans
    20. Buechel ME, Enserro D, Burger RA, Brady MF, Wade K, Secord AA, Nixon AB, Mirniaharikandehei S, Liu H, Zheng B, O'Malley DM, Gray H, Tewari KS, Mannel RS, Birrer MJ, Moore KN. Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC). Gynecol Oncol. 2021 05; 161(2):382-388. PMID: 33712274.
      Citations: 6     Fields:    Translation:Humans
    21. Hossen MN, Elechalawar CK, Sjoelund V, Moore K, Mannel R, Bhattacharya R, Mukherjee P. Experimental conditions influence the formation and composition of the corona around gold nanoparticles. Cancer Nanotechnol. 2021; 12(1):1. PMID: 33456622.
      Citations: 8     
    22. Miller DS, Filiaci VL, Mannel RS, Cohn DE, Matsumoto T, Tewari KS, DiSilvestro P, Pearl ML, Argenta PA, Powell MA, Zweizig SL, Warshal DP, Hanjani P, Carney ME, Huang H, Cella D, Zaino R, Fleming GF. Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209). J Clin Oncol. 2020 11 20; 38(33):3841-3850. PMID: 33078978.
      Citations: 86     Fields:    Translation:HumansCTClinical Trials
    23. Bertagnolli MM, Blanke CD, Curran WJ, Hawkins DS, Mannel RS, O'Dwyer PJ, Schnall MD, Wolmark N. What happened to the US cancer cooperative groups? A status update ten years after the Institute of Medicine report. Cancer. 2020 12 01; 126(23):5022-5029. PMID: 32970346.
      Citations: 9     Fields:    Translation:Humans
    24. Chen X, Liu W, Thai TC, Castellano T, Gunderson CC, Moore K, Mannel RS, Liu H, Zheng B, Qiu Y. Developing a new radiomics-based CT image marker to detect lymph node metastasis among cervical cancer patients. Comput Methods Programs Biomed. 2020 Dec; 197:105759. PMID: 33007594.
      Citations: 8     Fields:    Translation:Humans
    25. Tewari KS, Sill MW, Coleman RL, Aghajanian C, Mannel R, DiSilvestro PA, Powell M, Randall LM, Farley J, Rubin SC, Monk BJ. Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2020 10; 159(1):79-87. PMID: 32723679.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    26. Alvarez Secord A, Bell Burdett K, Owzar K, Tritchler D, Sibley AB, Liu Y, Starr MD, Brady JC, Lankes HA, Hurwitz HI, Mannel RS, Tewari KS, O'Malley DM, Gray H, Bakkum-Gamez JN, Fujiwara K, Boente M, Deng W, Burger RA, Birrer MJ, Nixon AB. Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218. Clin Cancer Res. 2020 03 15; 26(6):1288-1296. PMID: 31919136.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    27. Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim JW, Park SY, Kim BG, Nam JH, Fujiwara K, Walker JL, Casey AC, Alvarez Secord A, Rubin S, Chan JK, DiSilvestro P, Davidson SA, Cohn DE, Tewari KS, Basen-Engquist K, Huang HQ, Brady MF, Mannel RS. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. N Engl J Med. 2019 11 14; 381(20):1929-1939. PMID: 31722153.
      Citations: 101     Fields:    Translation:HumansCTClinical Trials
    28. Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, Bookman MA, Fleming GF, Huang H, Homesley HD, Fowler JM, Greer BE, Boente M, Liang SX, Ye C, Bais C, Randall LM, Chan JK, Ferriss JS, Coleman RL, Aghajanian C, Herzog TJ, DiSaia PJ, Copeland LJ, Mannel RS, Birrer MJ, Monk BJ. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. J Clin Oncol. 2019 09 10; 37(26):2317-2328. PMID: 31216226.
      Citations: 165     Fields:    Translation:HumansCTClinical Trials
    29. Fuh KC, Java JJ, Chan JK, Kapp DS, Monk BJ, Burger RA, Young RC, Alberts DS, McGuire WP, Markman M, Bell J, Ozols RF, Armstrong DK, Aghajanian C, Bookman MA, Mannel RS. Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients. Gynecol Oncol. 2019 08; 154(2):420-425. PMID: 31229298.
      Citations: 11     Fields:    Translation:Humans
    30. Walker JL, Brady MF, Wenzel L, Fleming GF, Huang HQ, DiSilvestro PA, Fujiwara K, Alberts DS, Zheng W, Tewari KS, Cohn DE, Powell MA, Van Le L, Davidson SA, Gray HJ, Rose PG, Aghajanian C, Myers T, Alvarez Secord A, Rubin SC, Mannel RS. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2019 06 01; 37(16):1380-1390. PMID: 31002578.
      Citations: 80     Fields:    Translation:HumansCTClinical Trials
    31. Randall ME, Filiaci V, McMeekin DS, von Gruenigen V, Huang H, Yashar CM, Mannel RS, Kim JW, Salani R, DiSilvestro PA, Burke JJ, Rutherford T, Spirtos NM, Terada K, Anderson PR, Brewster WR, Small W, Aghajanian CA, Miller DS. Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer. J Clin Oncol. 2019 07 20; 37(21):1810-1818. PMID: 30995174.
      Citations: 111     Fields:    Translation:HumansCTClinical Trials
    32. Bertagnolli MM, Blaney SM, Blanke CD, Curran WJ, Dancey J, Mannel RS, O'Dwyer PJ, Schnall MD, Wolmark N. Current Activities of the Coalition of Cancer Cooperative Groups. J Natl Cancer Inst. 2019 01 01; 111(1):11-18. PMID: 30544145.
      Citations: 1     Fields:    Translation:Humans
    33. Matulonis UA, Sill MW, Makker V, Mutch DG, Carlson JW, Darus CJ, Mannel RS, Bender DP, Crane EK, Aghajanian C. A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2019 03; 152(3):548-553. PMID: 30587441.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    34. Zargari A, Du Y, Heidari M, Thai TC, Gunderson CC, Moore K, Mannel RS, Liu H, Zheng B, Qiu Y. Prediction of chemotherapy response in ovarian cancer patients using a new clustered quantitative image marker. Phys Med Biol. 2018 08 06; 63(15):155020. PMID: 30010611.
      Citations: 18     Fields:    Translation:Humans
    35. Ahmed A, Deng W, Tew W, Bender D, Mannel RS, Littell RD, DeNittis AS, Edelson M, Morgan M, Carlson J, Darus CJ, Fleury AC, Modesitt S, Olawaiye A, Evans A, Fleming GF. Pre-operative assessment and post-operative outcomes of elderly women with gynecologic cancers, primary analysis of NRG CC-002: An NRG oncology group/gynecologic oncology group study. Gynecol Oncol. 2018 08; 150(2):300-305. PMID: 29807694.
      Citations: 8     Fields:    Translation:Humans
    36. Eskander RN, Kauderer J, Tewari KS, Mannel RS, Bristow RE, O'Malley DM, Rubin SC, Glaser GE, Hamilton CA, Fujiwara K, Huh WK, Ueland F, Stephan JM, Burger RA. Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2018 06; 149(3):525-530. PMID: 29550184.
      Citations: 12     Fields:    Translation:Humans
    37. Norquist BM, Brady MF, Harrell MI, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Burger RA, Tewari KS, Backes F, Mannel RS, Glaser G, Bailey C, Rubin S, Soper J, Lankes HA, Ramirez NC, King MC, Birrer MJ, Swisher EM. Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. Clin Cancer Res. 2018 02 15; 24(4):777-783. PMID: 29191972.
      Citations: 106     Fields:    Translation:HumansCells
    38. Gee MS, Atri M, Bandos AI, Mannel RS, Gold MA, Lee SI. Identification of Distant Metastatic Disease in Uterine Cervical and Endometrial Cancers with FDG PET/CT: Analysis from the ACRIN 6671/GOG 0233 Multicenter Trial. Radiology. 2018 04; 287(1):176-184. PMID: 29185901.
      Citations: 32     Fields:    Translation:Humans
    39. Seamon LG, Java JJ, Monk BJ, Penson RT, Brown J, Mannel RS, Oaknin A, Leitao MM, Eisenhauer EL, Long HJ, Liao SY, Tewari KS. Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study. Br J Cancer. 2018 01; 118(2):162-170. PMID: 29182608.
      Citations: 7     Fields:    Translation:Humans
    40. Bais C, Mueller B, Brady MF, Mannel RS, Burger RA, Wei W, Marien KM, Kockx MM, Husain A, Birrer MJ. Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses. J Natl Cancer Inst. 2017 11 01; 109(11). PMID: 29059426.
      Citations: 48     Fields:    Translation:HumansCTClinical Trials
    41. Devor EJ, Miecznikowski J, Schickling BM, Gonzalez-Bosquet J, Lankes HA, Thaker P, Argenta PA, Pearl ML, Zweizig SL, Mannel RS, Brown A, Ramirez NC, Ioffe OB, Park KJ, Creasman WT, Birrer MJ, Mutch D, Leslie KK. Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 12; 147(3):648-653. PMID: 28969912.
      Citations: 15     Fields:    Translation:Humans
    42. Oliver KE, Brady WE, Birrer M, Gershenson DM, Fleming G, Copeland LJ, Tewari K, Argenta PA, Mannel RS, Secord AA, Stephan JM, Mutch DG, Stehman FB, Muggia FM, Rose PG, Armstrong DK, Bookman MA, Burger RA, Farley JH. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. Gynecol Oncol. 2017 11; 147(2):243-249. PMID: 28807367.
      Citations: 40     Fields:    Translation:Humans
    43. Danala G, Thai T, Gunderson CC, Moxley KM, Moore K, Mannel RS, Liu H, Zheng B, Qiu Y. Applying Quantitative CT Image Feature Analysis to Predict Response of Ovarian Cancer Patients to Chemotherapy. Acad Radiol. 2017 10; 24(10):1233-1239. PMID: 28554551.
      Citations: 21     Fields:    Translation:Humans
    44. Chakraborty PK, Mustafi SB, Xiong X, Dwivedi SKD, Nesin V, Saha S, Zhang M, Dhanasekaran D, Jayaraman M, Mannel R, Moore K, McMeekin S, Yang D, Zuna R, Ding K, Tsiokas L, Bhattacharya R, Mukherjee P. MICU1 drives glycolysis and chemoresistance in ovarian cancer. Nat Commun. 2017 05 22; 8:14634. PMID: 28530221.
      Citations: 80     Fields:    Translation:HumansAnimalsCells
    45. Monk BJ, Brady MF, Aghajanian C, Lankes HA, Rizack T, Leach J, Fowler JM, Higgins R, Hanjani P, Morgan M, Edwards R, Bradley W, Kolevska T, Foukas P, Swisher EM, Anderson KS, Gottardo R, Bryan JK, Newkirk M, Manjarrez KL, Mannel RS, Hershberg RM, Coukos G. A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study. Ann Oncol. 2017 May 01; 28(5):996-1004. PMID: 28453702.
      Citations: 36     Fields:    Translation:HumansCTClinical Trials
    46. Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 06; 18(6):779-791. PMID: 28438473.
      Citations: 240     Fields:    Translation:HumansCTClinical Trials
    47. Creasman WT, Ali S, Mutch DG, Zaino RJ, Powell MA, Mannel RS, Backes FJ, DiSilvestro PA, Argenta PA, Pearl ML, Lele SB, Guntupalli SR, Waggoner S, Spirtos N, Boggess JF, Edwards RP, Filiaci VL, Miller DS. Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol. Gynecol Oncol. 2017 06; 145(3):519-525. PMID: 28392124.
      Citations: 22     Fields:    Translation:Humans
    48. Jeske YW, Ali S, Byron SA, Gao F, Mannel RS, Ghebre RG, DiSilvestro PA, Lele SB, Pearl ML, Schmidt AP, Lankes HA, Ramirez NC, Rasty G, Powell M, Goodfellow PJ, Pollock PM. FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 05; 145(2):366-373. PMID: 28314589.
      Citations: 19     Fields:    Translation:Humans
    49. Thaker PH, Salani R, Brady WE, Lankes HA, Cohn DE, Mutch DG, Mannel RS, Bell-McGuinn KM, Di Silvestro PA, Jelovac D, Carter JS, Duan W, Resnick KE, Dizon DS, Aghajanian C, Fracasso PM. A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852). Ann Oncol. 2017 03 01; 28(3):505-511. PMID: 27998970.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    50. Ng CS, Zhang Z, Lee SI, Marques HS, Burgers K, Su F, Bauza J, Mannel RS, Walker JL, Huh WK, Rubin SC, DiSilvestro P, Martin LP, Chan JK, Bookman MA, Coleman RL, Lee TY. CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study. Clin Cancer Res. 2017 Jul 15; 23(14):3684-3691. PMID: 28174234.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    51. von Gruenigen VE, Huang HQ, Beumer JH, Lankes HA, Tew W, Herzog T, Hurria A, Mannel RS, Rizack T, Landrum LM, Rose PG, Salani R, Bradley WH, Rutherford TJ, Higgins RV, Secord AA, Fleming G. Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 03; 144(3):459-467. PMID: 28089376.
      Citations: 19     Fields:    Translation:Humans
    52. Atri M, Zhang Z, Dehdashti F, Lee SI, Marques H, Ali S, Koh WJ, Mannel RS, DiSilvestro P, King SA, Pearl M, Zhou X, Plante M, Moxley KM, Gold M. Utility of PET/CT to Evaluate Retroperitoneal Lymph Node Metastasis in High-Risk Endometrial Cancer: Results of ACRIN 6671/GOG 0233 Trial. Radiology. 2017 05; 283(2):450-459. PMID: 28051912.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    53. Winder AD, Maniar KP, Wei JJ, Liu D, Scholtens DM, Lurain JR, Schink JC, Buttin BM, Filiaci VL, Lankes HA, Ramirez NC, Park K, Singh M, Lieberman RW, Mannel RS, Powell MA, Backes FJ, Mathews CA, Pearl ML, Secord AA, Peace DJ, Mutch DG, Creasman WT, Kim JJ. Synuclein-? in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study. Cancer. 2017 04 01; 123(7):1144-1155. PMID: 27926776.
      Citations: 7     Fields:    Translation:Humans
    54. Thomas ED, Nugent EK, MacAllister MC, Moxley KM, Landrum L, L Walker J, McMeekin DS, Mannel RS, McGwin G, Moore KN. Effectiveness of cyanoacrylate microbial sealant in the reduction of surgical site infection in gynecologic oncology procedures: A phase III single institution prospective randomized trial. Gynecol Oncol. 2017 Jan; 144(1):193-199. PMID: 27836205.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    55. Fader AN, Java J, Tenney M, Ricci S, Gunderson CC, Temkin SM, Spirtos N, Kushnir CL, Pearl ML, Zivanovic O, Tewari KS, O'Malley D, Hartenbach EM, Hamilton CA, Gould NS, Mannel RS, Rodgers W, Walker JL. Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis. Gynecol Oncol. 2016 Dec; 143(3):460-465. PMID: 27743738.
      Citations: 36     Fields:    Translation:HumansCTClinical Trials
    56. Osborne RJ, Filiaci VL, Schink JC, Mannel RS, Behbakht K, Hoffman JS, Spirtos NM, Chan JK, Tidy JA, Miller DS. Second Curettage for Low-Risk Nonmetastatic Gestational Trophoblastic Neoplasia. Obstet Gynecol. 2016 Sep; 128(3):535-542. PMID: 27500329.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    57. Gunderson CC, Rowland MR, Wright DL, Andrade KL, Mannel RS, McMeekin DS, Moore KN. Initiation of a formalized precision medicine program in gynecologic oncology. Gynecol Oncol. 2016 Apr; 141(1):24-8. PMID: 27016225.
      Citations: 8     Fields:    Translation:Humans
    58. Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Yi Q, Burger RA, Chan JK, Davidson SA, Mannel RS, DiSilvestro PA, Lankes HA, Ramirez NC, King MC, Swisher EM, Birrer MJ. Inherited Mutations in Women With Ovarian Carcinoma. JAMA Oncol. 2016 Apr; 2(4):482-90. PMID: 26720728.
      Citations: 327     Fields:    Translation:Humans
    59. Moore KN, Mannel RS. Is the NCI MATCH trial a match for gynecologic oncology? Gynecol Oncol. 2016 Jan; 140(1):161-6. PMID: 26586415.
      Citations: 10     Fields:    Translation:Humans
    60. Hess LM, Huang HQ, Hanlon AL, Robinson WR, Johnson R, Chambers SK, Mannel RS, Puls L, Davidson SA, Method M, Lele S, Havrilesky L, Nelson T, Alberts DS. Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2015 Dec; 139(3):541-5. PMID: 26456812.
      Citations: 22     Fields:    Translation:Humans
    61. Bender D, Sill MW, Lankes HA, Reyes HD, Darus CJ, Delmore JE, Rotmensch J, Gray HJ, Mannel RS, Schilder JM, Hunter MI, McCourt CK, Samuelson MI, Leslie KK. A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Sep; 138(3):507-12. PMID: 26186911.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    62. Viswanathan AN, Moughan J, Miller BE, Xiao Y, Jhingran A, Portelance L, Bosch WR, Matulonis UA, Horowitz NS, Mannel RS, Souhami L, Erickson BA, Winter KA, Small W, Gaffney DK. NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer. Cancer. 2015 Jul 01; 121(13):2156-63. PMID: 25847373.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    63. Hensley ML, Miller A, O'Malley DM, Mannel RS, Behbakht K, Bakkum-Gamez JN, Michael H. Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol. 2015 Apr 01; 33(10):1180-5. PMID: 25713428.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    64. Atri M, Zhang Z, Marques H, Gorelick J, Harisinghani M, Sohaib A, Koh DM, Raman S, Gee M, Choi H, Landrum L, Mannel R, Chuang L, Yu JQ, McCourt CK, Gold M. Utility of preoperative ferumoxtran-10 MRI to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN 6671/GOG 0233. Eur J Radiol Open. 2015; 2:11-18. PMID: 25774381.
      Citations: 6     
    65. Zaino RJ, Brady WE, Todd W, Leslie K, Fischer EG, Horowitz NS, Mannel RS, Walker JL, Ivanovic M, Duska LR. Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: a Gynecologic Oncology Group study. Int J Gynecol Pathol. 2014 Nov; 33(6):543-53. PMID: 25272292.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    66. Slaughter KN, Moore KN, Mannel RS. Anti-angiogenic therapy versus dose-dense paclitaxel therapy for frontline treatment of epithelial ovarian cancer: review of phase III randomized clinical trials. Curr Oncol Rep. 2014 Nov; 16(11):412. PMID: 25292279.
      Citations: 3     Fields:    Translation:Humans
    67. Mannel RS, Moore K. Research: An event or an environment? Gynecol Oncol. 2014 Sep; 134(3):441-2. PMID: 25199577.
      Citations: 3     Fields:    Translation:Humans
    68. Herzog TJ, Alvarez RD, Secord A, Goff BA, Mannel RS, Monk BJ, Coleman RL. SGO guidance document for clinical trial designs in ovarian cancer: a changing paradigm. Gynecol Oncol. 2014 Oct; 135(1):3-7. PMID: 25124162.
      Citations: 3     Fields:    Translation:Humans
    69. Duska LR, Blessing JA, Rotmensch J, Mannel RS, Hanjani P, Rose PG, Dizon DS. A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2014 Oct; 135(1):44-8. PMID: 25091619.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    70. Miller DS, Blessing JA, Ramondetta LM, Pham HQ, Tewari KS, Landrum LM, Brown J, Mannel RS. Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic oncology group. J Clin Oncol. 2014 Sep 01; 32(25):2744-9. PMID: 25071133.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    71. Powell MA, Sill MW, Goodfellow PJ, Benbrook DM, Lankes HA, Leslie KK, Jeske Y, Mannel RS, Spillman MA, Lee PS, Hoffman JS, McMeekin DS, Pollock PM. A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2014 Oct; 135(1):38-43. PMID: 25019571.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    72. Herzog TJ, Armstrong DK, Brady MF, Coleman RL, Einstein MH, Monk BJ, Mannel RS, Thigpen JT, Umpierre SA, Villella JA, Alvarez RD. Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. Gynecol Oncol. 2014 Jan; 132(1):8-17. PMID: 24239753.
      Citations: 26     Fields:    Translation:Humans
    73. Landrum LM, Nugent EK, Zuna RE, Syzek E, Mannel RS, Moore KN, Walker JL, McMeekin DS. Phase II trial of vaginal cuff brachytherapy followed by chemotherapy in early stage endometrial cancer patients with high-intermediate risk factors. Gynecol Oncol. 2014 Jan; 132(1):50-4. PMID: 24219982.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    74. Leslie KK, Sill MW, Fischer E, Darcy KM, Mannel RS, Tewari KS, Hanjani P, Wilken JA, Baron AT, Godwin AK, Schilder RJ, Singh M, Maihle NJ. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Jun; 129(3):486-94. PMID: 23438670.
      Citations: 19     Fields:    Translation:HumansCellsCTClinical Trials
    75. Schilder RJ, Sill MW, Lankes HA, Gold MA, Mannel RS, Modesitt SC, Hanjani P, Bonebrake AJ, Sood AK, Godwin AK, Hu W, Alpaugh RK. A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Apr; 129(1):86-91. PMID: 23321064.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    76. Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, Mannel R, Yamada SD, Mutch D, Rodgers WH, Birrer M, Gershenson DM. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013 Feb; 14(2):134-40. PMID: 23261356.
      Citations: 157     Fields:    Translation:HumansCellsCTClinical Trials
    77. Monk BJ, Huang HQ, Burger RA, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Liang SX, Wenzel L. Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2013 Mar; 128(3):573-8. PMID: 23219660.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    78. Moore KN, Sill MW, Miller DS, McCourt C, De Geest K, Rose PG, Cardenes HR, Mannel RS, Farley JH, Schilder RJ, Fracasso PM. A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study. Gynecol Oncol. 2012 Dec; 127(3):456-61. PMID: 22960004.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    79. Gould N, Sill MW, Mannel RS, Thaker PH, DiSilvestro PA, Waggoner SE, Yamada SD, Armstrong DK, Fracasso PM, Walker JL. A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Dec; 127(3):506-10. PMID: 22943879.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    80. Schilder RJ, Brady WE, Lankes HA, Fiorica JV, Shahin MS, Zhou XC, Mannel RS, Pathak HB, Hu W, Alpaugh RK, Sood AK, Godwin AK. Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Oct; 127(1):70-4. PMID: 22710075.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    81. Walker JL, Piedmonte MR, Spirtos NM, Eisenkop SM, Schlaerth JB, Mannel RS, Barakat R, Pearl ML, Sharma SK. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol. 2012 Mar 01; 30(7):695-700. PMID: 22291074.
      Citations: 180     Fields:    Translation:Humans
    82. Dewdney SB, Kizer NT, Andaya AA, Babb SA, Luo J, Mutch DG, Schmidt AP, Brinton LA, Broaddus RR, Ramirez NC, Huettner PC, McMeekin DS, Darcy K, Ali S, Judson PL, Mannel RS, Lele SB, O'Malley DM, Goodfellow PJ. Uterine serous carcinoma: increased familial risk for lynch-associated malignancies. Cancer Prev Res (Phila). 2012 Mar; 5(3):435-43. PMID: 22246618.
      Citations: 6     Fields:    Translation:HumansCells
    83. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011 Dec 29; 365(26):2473-83. PMID: 22204724.
      Citations: 918     Fields:    Translation:HumansCTClinical Trials
    84. Gould N, Sill MW, Mannel RS, Thaker PH, Disilvestro P, Waggoner S, Yamada SD, Armstrong DK, Wenzel L, Huang H, Fracasso PM, Walker JL. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Apr; 125(1):54-8. PMID: 22155262.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    85. Tewari KS, Filiaci VL, Spirtos NM, Mannel RS, Thigpen JT, Cibull ML, Monk BJ, Randall ME. Association of number of positive nodes and cervical stroma invasion with outcome of advanced endometrial cancer treated with chemotherapy or whole abdominal irradiation: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Apr; 125(1):87-93. PMID: 22155678.
      Citations: 12     Fields:    Translation:Humans
    86. Nugent EK, Bishop EA, Mathews CA, Moxley KM, Tenney M, Mannel RS, Walker JL, Moore KN, Landrum LM, McMeekin DS. Do uterine risk factors or lymph node metastasis more significantly affect recurrence in patients with endometrioid adenocarcinoma? Gynecol Oncol. 2012 Apr; 125(1):94-8. PMID: 22155415.
      Citations: 20     Fields:    Translation:Humans
    87. Garcia AA, Sill MW, Lankes HA, Godwin AK, Mannel RS, Armstrong DK, Carolla RL, Liepman MK, Spirtos NM, Fischer EG, Leslie KK. A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2012 Mar; 124(3):569-74. PMID: 22037316.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    88. Dizon DS, Sill MW, Gould N, Rubin SC, Yamada SD, Debernardo RL, Mannel RS, Eisenhauer EL, Duska LR, Fracasso PM. Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2011 Nov; 123(2):182-6. PMID: 21820161.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    89. Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, Schilder RJ, Cai KQ, Godwin AK, Alpaugh RK. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol. 2011 Oct; 123(1):19-26. PMID: 21752435.
      Citations: 91     Fields:    Translation:HumansCellsCTClinical Trials
    90. Landrum LM, Hyde J, Mannel RS, McMeekin DS, Moore KN, Walker JL. Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer. Gynecol Oncol. 2011 Sep; 122(3):527-31. PMID: 21664657.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    91. Mannel RS, Brady MF, Kohn EC, Hanjani P, Hiura M, Lee R, Degeest K, Cohn DE, Monk BJ, Michael H. A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2011 Jul; 122(1):89-94. PMID: 21529904.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    92. Thigpen T, duBois A, McAlpine J, DiSaia P, Fujiwara K, Hoskins W, Kristensen G, Mannel R, Markman M, Pfisterer J, Quinn M, Reed N, Swart AM, Berek J, Colombo N, Freyer G, Gallardo D, Plante M, Poveda A, Rubinstein L, Bacon M, Kitchener H, Stuart GC. First-line therapy in ovarian cancer trials. Int J Gynecol Cancer. 2011 May; 21(4):756-62. PMID: 21543937.
      Citations: 38     Fields:    Translation:Humans
    93. Usha L, Sill MW, Darcy KM, Benbrook DM, Hurteau JA, Michelin DP, Mannel RS, Hanjani P, De Geest K, Godwin AK. A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. Gynecol Oncol. 2011 Jun 01; 121(3):455-61. PMID: 21414654.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    94. Morgan MA, Sill MW, Fujiwara K, Greer B, Rubin SC, Degeest K, Yamada SD, Waggoner S, Coleman RL, Walker JL, Mannel RS. A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2011 May 01; 121(2):264-8. PMID: 21277623.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    95. Osborne RJ, Filiaci V, Schink JC, Mannel RS, Alvarez Secord A, Kelley JL, Provencher D, Scott Miller D, Covens AL, Lage JM. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. J Clin Oncol. 2011 Mar 01; 29(7):825-31. PMID: 21263100.
      Citations: 40     Fields:    Translation:HumansCTClinical Trials
    96. Trimble EL, Birrer MJ, Hoskins WJ, Marth C, Petryshyn R, Quinn M, Thomas GM, Kitchener HC, Aghajanian C, Alberts DS, Armstrong D, Brown J, Coleman RL, Colombo N, Eisenhauer E, Friedlander M, Fujiwara K, Hunsberger S, Kaye S, Ledermann JA, Lee S, Look K, Mannel R, McNeish IA, Minasian L, Oza A, Paul J, Poveda A, Pujade-Lauraine E, Schoenfeldt M, Swart AM, von Gruenigen V, Wenzel L. Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009. Int J Gynecol Cancer. 2010 Oct; 20(7):1290-8. PMID: 21151709.
      Citations: 4     Fields:    Translation:Humans
    97. Hurteau JA, Brady MF, Darcy KM, McGuire WP, Edmonds P, Pearl ML, Ivanov I, Tewari KS, Mannel RS, Zanotti K, Benbrook DM. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecol Oncol. 2010 Dec; 119(3):444-50. PMID: 20846715.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    98. Tiersten AD, Sill MW, Knight D, Muggia F, Garcia AA, Swensen R, Warshal DP, Mannel RS, Fracasso PM. A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2010 Sep; 118(3):303-7. PMID: 20547415.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    99. Powell MA, Filiaci VL, Rose PG, Mannel RS, Hanjani P, Degeest K, Miller BE, Susumu N, Ueland FR. Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. J Clin Oncol. 2010 Jun 01; 28(16):2727-31. PMID: 20421537.
      Citations: 50     Fields:    Translation:HumansCTClinical Trials
    100. Rocereto TF, Brady WE, Shahin MS, Hoffman JS, Small L, Rotmensch J, Mannel RS. A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study. Gynecol Oncol. 2010 Mar; 116(3):332-4. PMID: 19922989.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    101. Walker JL, Piedmonte MR, Spirtos NM, Eisenkop SM, Schlaerth JB, Mannel RS, Spiegel G, Barakat R, Pearl ML, Sharma SK. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol. 2009 Nov 10; 27(32):5331-6. PMID: 19805679.
      Citations: 292     Fields:    Translation:Humans
    102. Alvarez RD, Mannel R, García AA, Gallion HH, Lucci J, Kilgore LC, Numnum TM, Zou SX, Orlando M, Tai DF. Fixed-dose rate gemcitabine plus carboplatin in relapsed, platinum-sensitive ovarian cancer patients: results of a three-arm Phase I study. Gynecol Oncol. 2009 Dec; 115(3):389-95. PMID: 19800673.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    103. Aghajanian C, Blessing JA, Darcy KM, Reid G, DeGeest K, Rubin SC, Mannel RS, Rotmensch J, Schilder RJ, Riordan W. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2009 Nov; 115(2):215-20. PMID: 19712963.
      Citations: 37     Fields:    Translation:HumansCTClinical Trials
    104. Schilder RJ, Sill MW, Lee YC, Mannel R. A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Int J Gynecol Cancer. 2009 Jul; 19(5):929-33. PMID: 19574787.
      Citations: 36     Fields:    Translation:HumansCTClinical Trials
    105. Moore KN, Frank SG, Alward EK, Landrum LM, Myers TK, Walker JL, Gold MA, McMeekin DS, Vesely SK, Mannel RS. Adjuvant chemotherapy for the "oldest old" ovarian cancer patients: can we anticipate toxicity-related treatment failure in a vulnerable population? Cancer. 2009 Apr 01; 115(7):1472-80. PMID: 19235786.
      Citations: 1     Fields:    Translation:Humans
    106. Miller DS, Blessing JA, Krasner CN, Mannel RS, Hanjani P, Pearl ML, Waggoner SE, Boardman CH. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol. 2009 Jun 01; 27(16):2686-91. PMID: 19332726.
      Citations: 77     Fields:    Translation:HumansCTClinical Trials
    107. Fowler JM, Brady WE, Grigsby PW, Cohn DE, Mannel RS, Rader JS. Sequential chemotherapy and irradiation in advanced stage endometrial cancer: A Gynecologic Oncology Group phase I trial of doxorubicin-cisplatin followed by whole abdomen irradiation. Gynecol Oncol. 2009 Mar; 112(3):553-7. PMID: 19135232.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    108. Garcia AA, Blessing JA, Nolte S, Mannel RS. A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group. Gynecol Oncol. 2008 Oct; 111(1):22-6. PMID: 18675446.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    109. Morgan MA, Darcy KM, Rose PG, DeGeest K, Bookman MA, Aikins JK, Sill MW, Mannel RS, Allievi C, Egorin MJ. Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group. Gynecol Oncol. 2008 Sep; 110(3):329-35. PMID: 18597837.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    110. Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2008 Jun; 109(3):329-34. PMID: 18534250.
      Citations: 114     Fields:    Translation:HumansCTClinical Trials
    111. Moore KN, Reid MS, Fong DN, Myers TK, Landrum LM, Moxley KM, Walker JL, McMeekin DS, Mannel RS. Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply? Gynecol Oncol. 2008 Aug; 110(2):133-9. PMID: 18495221.
      Citations: 21     Fields:    Translation:Humans
    112. Landrum LM, Rutledge TL, Osunkoya AO, Mannel R. Uterine leiomyoma with associated pseudo-Meigs syndrome mimicking ovarian carcinoma. J Okla State Med Assoc. 2008 Feb; 101(2):38-9. PMID: 18361033.
      Citations: 3     Fields:    Translation:Humans
    113. Secord AA, Blessing JA, Armstrong DK, Rodgers WH, Miner Z, Barnes MN, Lewandowski G, Mannel RS. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. Gynecol Oncol. 2008 Mar; 108(3):493-9. PMID: 18191993.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    114. Spriggs DR, Brady MF, Vaccarello L, Clarke-Pearson DL, Burger RA, Mannel R, Boggess JF, Lee RB, Hanly M. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007 Oct 01; 25(28):4466-71. PMID: 17906207.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    115. Wolfson AH, Brady MF, Rocereto T, Mannel RS, Lee YC, Futoran RJ, Cohn DE, Ioffe OB. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol. 2007 Nov; 107(2):177-85. PMID: 17822748.
      Citations: 58     Fields:    Translation:HumansCTClinical Trials
    116. Eddy GL, Bundy BN, Creasman WT, Spirtos NM, Mannel RS, Hannigan E, O'Connor D. Treatment of ("bulky") stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology group. Gynecol Oncol. 2007 Aug; 106(2):362-9. PMID: 17493669.
      Citations: 50     Fields:    Translation:HumansCTClinical Trials
    117. Mannel R, Mannel RS. Staffing for hospital lactation programs: recommendations from a tertiary care teaching hospital. J Hum Lact. 2006 Nov; 22(4):409-17. PMID: 17062786.
      Citations: 4     Fields:    Translation:Humans
    118. Bruner DW, Barsevick A, Tian C, Randall M, Mannel R, Cohn DE, Sorosky J, Spirtos NM. Randomized trial results of quality of life comparing whole abdominal irradiation and combination chemotherapy in advanced endometrial carcinoma: A gynecologic oncology group study. Qual Life Res. 2007 Feb; 16(1):89-100. PMID: 17033909.
      Citations: 16     Fields:    Translation:Humans
    119. Calkins A, Stehman FB, Bundy B, Benda JA, Mannel RS, Seago P, Cappuccini F, Alvarez RD, Monk BJ, Maiman M. Human immunodeficiency virus testing in patients with invasive cervical carcinoma: a prospective trial of the gynecologic oncology group. Int J Gynecol Cancer. 2006 Mar-Apr; 16(2):660-3. PMID: 16681743.
      Citations:    Fields:    Translation:HumansCells
    120. Barakat RR, Bundy BN, Spirtos NM, Bell J, Mannel RS. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2006 Feb 01; 24(4):587-92. PMID: 16446331.
      Citations: 43     Fields:    Translation:Humans
    121. Tillmanns TD, Falkner CA, Engle DB, Wan JY, Mannel RS, Walker JL, Johnson GA, McMeekin DS, Zuna R, Gold MA. Preoperative predictors of positive margins after loop electrosurgical excisional procedure-Cone. Gynecol Oncol. 2006 Feb; 100(2):379-84. PMID: 16321430.
      Citations: 5     Fields:    Translation:Humans
    122. Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, Thigpen JT, Benda JA. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2006 Jan 01; 24(1):36-44. PMID: 16330675.
      Citations: 215     Fields:    Translation:HumansCTClinical Trials
    123. Covens A, Blessing J, Bender D, Mannel R, Morgan M. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2006 Mar; 100(3):586-90. PMID: 16249022.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    124. Rutledge TL, Gold MA, McMeekin DS, Huh WK, Powell MA, Lewin SN, Mutch DG, Johnson GA, Walker JL, Mannel RS. Carcinosarcoma of the ovary-a case series. Gynecol Oncol. 2006 Jan; 100(1):128-32. PMID: 16213011.
      Citations: 21     Fields:    Translation:Humans
    125. Greer BE, Bundy BN, Ozols RF, Fowler JM, Clarke-Pearson D, Burger RA, Mannel R, DeGeest K, Hartenbach EM, Baergen RN, Copeland LJ. Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study. Gynecol Oncol. 2005 Oct; 99(1):71-9. PMID: 16039699.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    126. Garcia AA, Blessing JA, Lenz HJ, Darcy KM, Mannel RS, Miller DS, Husseinzadeh N. Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study. Gynecol Oncol. 2005 Mar; 96(3):810-7. PMID: 15721430.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    127. Scribner DR, Baldwin J, Mannel RS. Gynecologic oncologists' perceptions of fellowship training. J Reprod Med. 2005 Jan; 50(1):29-34. PMID: 15730170.
      Citations: 4     Fields:    Translation:Humans
    128. du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Neijt JP, Oza A, Ozols R, Parmar M, Pecorelli S, Pfisterer J, Poveda A, Provencher D, Pujade-Lauraine E, Randall M, Rochon J, Rustin G, Sagae S, Stehman F, Stuart G, Trimble E, Vasey P, Vergote I, Verheijen R, Wagner U. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol. 2005; 16 Suppl 8:viii7-viii12. PMID: 16239238.
      Citations: 119     Fields:    Translation:Humans
    129. Rutledge TL, Kamelle SA, Tillmanns TD, Gould NS, Wright JD, Cohn DE, Herzog TJ, Rader JS, Gold MA, Johnson GA, Walker JL, Mannel RS, McMeekin DS. A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference? Gynecol Oncol. 2004 Oct; 95(1):70-6. PMID: 15385112.
      Citations: 9     Fields:    Translation:Humans
    130. McMeekin DS, Tillmanns T, Chaudry T, Gold M, Johnson G, Walker J, Mannel R. Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer. Gynecol Oncol. 2004 Oct; 95(1):157-64. PMID: 15385126.
      Citations: 8     Fields:    Translation:Humans
    131. Kamelle SA, Rutledge TL, Tillmanns TD, Gould NS, Cohn DE, Wright J, Herzog TJ, Rader JS, Gold MA, Johnson GA, Walker JL, Mannel RS, McMeekin DS. Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply? Gynecol Oncol. 2004 Aug; 94(2):249-55. PMID: 15297159.
      Citations: 4     Fields:    Translation:Humans
    132. Fiorica JV, Brunetto VL, Hanjani P, Lentz SS, Mannel R, Andersen W. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004 Jan; 92(1):10-4. PMID: 14751131.
      Citations: 60     Fields:    Translation:HumansCellsCTClinical Trials
    133. Shen-Gunther J, Mannel RS, Walker JL, Gold MA, Johnson GA. Outpatient implantation of a central venous access system in gynecologic oncology patients. J Reprod Med. 2003 Nov; 48(11):875-81. PMID: 14686020.
      Citations: 1     Fields:    Translation:Humans
    134. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003 Sep 01; 21(17):3194-200. PMID: 12860964.
      Citations: 633     Fields:    Translation:HumansCTClinical Trials
    135. Rose PG, Blessing JA, Buller RE, Mannel RS, Webster KD. Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 2003 May; 89(2):267-70. PMID: 12713990.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    136. Mannel RS, Walker JL, Gould N, Scribner DR, Kamelle S, Tillmanns T, McMeekin DS, Gold MA. Impact of individual physicians on enrollment of patients into clinical trials. Am J Clin Oncol. 2003 Apr; 26(2):171-3. PMID: 12714890.
      Citations: 19     Fields:    Translation:Humans
    137. Shen-Gunther J, Mannel RS. Ascites as a predictor of ovarian malignancy. Gynecol Oncol. 2002 Oct; 87(1):77-83. PMID: 12468346.
      Citations: 35     Fields:    Translation:Humans
    138. Bloss JD, Blessing JA, Behrens BC, Mannel RS, Rader JS, Sood AK, Markman M, Benda J. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2002 Apr 01; 20(7):1832-7. PMID: 11919241.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    139. Scribner DR, Walker JL, Johnson GA, McMeekin DS, Gold MA, Mannel RS. Laparoscopic pelvic and paraaortic lymph node dissection in the obese. Gynecol Oncol. 2002 Mar; 84(3):426-30. PMID: 11855882.
      Citations: 16     Fields:    Translation:Humans
    140. Mayr NA, Taoka T, Yuh WT, Denning LM, Zhen WK, Paulino AC, Gaston RC, Sorosky JI, Meeks SL, Walker JL, Mannel RS, Buatti JM. Method and timing of tumor volume measurement for outcome prediction in cervical cancer using magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2002 Jan 01; 52(1):14-22. PMID: 11777618.
      Citations: 58     Fields:    Translation:Humans
    141. Scribner DR, Walker JL, Johnson GA, McMeekin SD, Gold MA, Mannel RS. Surgical management of early-stage endometrial cancer in the elderly: is laparoscopy feasible? Gynecol Oncol. 2001 Dec; 83(3):563-8. PMID: 11733973.
      Citations: 20     Fields:    Translation:Humans
    142. McMeekin DS, Kamelle SA, Vasilev SA, Tillmanns TD, Gould NS, Scribner DR, Gold MA, Guruswamy S, Mannel RS. Ovarian cancer metastatic to the brain: what is the optimal management? J Surg Oncol. 2001 Nov; 78(3):194-200; discussion 200-1. PMID: 11745806.
      Citations: 21     Fields:    Translation:Humans
    143. Scribner DR, Walker JL, Johnson GA, McMeekin SD, Gold MA, Mannel RS. Laparoscopic pelvic and paraaortic lymph node dissection: analysis of the first 100 cases. Gynecol Oncol. 2001 Sep; 82(3):498-503. PMID: 11520146.
      Citations: 7     Fields:    Translation:Humans
    144. Gould N, Kamelle S, Tillmanns T, Scribner D, Gold M, Walker J, Mannel R. Predictors of complications after inguinal lymphadenectomy. Gynecol Oncol. 2001 Aug; 82(2):329-32. PMID: 11531288.
      Citations: 22     Fields:    Translation:Humans
    145. McMeekin DS, Lashbrook D, Gold M, Scribner DR, Kamelle S, Tillmanns TD, Mannel R. Nodal distribution and its significance in FIGO stage IIIc endometrial cancer. Gynecol Oncol. 2001 Aug; 82(2):375-9. PMID: 11531298.
      Citations: 16     Fields:    Translation:Humans
    146. Scribner DR, Kamelle SA, Gould N, Tillmanns T, Wilson MA, McMeekin S, Gold MA, Mannel RS. A retrospective analysis of radical hysterectomies done for cervical cancer: is there a role for the Pfannenstiel incision? Gynecol Oncol. 2001 Jun; 81(3):481-4. PMID: 11371142.
      Citations:    Fields:    Translation:Humans
    147. McMeekin DS, Lashbrook D, Gold M, Johnson G, Walker JL, Mannel R. Analysis of FIGO Stage IIIc endometrial cancer patients. Gynecol Oncol. 2001 May; 81(2):273-8. PMID: 11330962.
      Citations: 23     Fields:    Translation:Humans
    148. DiSilvestro PA, DiSilvestro JM, Lernhardt W, Pfahl M, Mannel RS. Treatment of cervical intraepithelial neoplasia levels 2 and 3 with adapalene, a retinoid-related molecule. J Low Genit Tract Dis. 2001 Jan; 5(1):33-7. PMID: 17043560.
      Citations: 5     Fields:    
    149. Mannel RS, Blessing JA, Boike G. Cisplatin and pentoxifylline in advanced or recurrent squamous cell carcinoma of the cervix: a phase II trial of the Gynecologic Oncology Group. Gynecol Oncol. 2000 Oct; 79(1):64-6. PMID: 11006033.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    150. Miller DS, Blessing JA, Kilgore LC, Mannel R, Van Le L. Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study. Am J Clin Oncol. 2000 Aug; 23(4):355-7. PMID: 10955863.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    151. Scribner DR, Mannel RS, Walker JL, Johnson GA. Cost analysis of laparoscopy versus laparotomy for early endometrial cancer. Gynecol Oncol. 1999 Dec; 75(3):460-3. PMID: 10600307.
      Citations: 7     Fields:    Translation:Humans
    152. Varia MA, Bundy BN, Deppe G, Mannel R, Averette HE, Rose PG, Connelly P. Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys. 1998 Dec 01; 42(5):1015-23. PMID: 9869224.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    153. Shen-Gunther J, Mannel RS, Walker JL, Johnson GA, Sienko AE. Laparoscopic paraaortic lymphadenectomy using laparosonic coagulating shears. J Am Assoc Gynecol Laparosc. 1998 Feb; 5(1):47-50. PMID: 9454876.
      Citations:    Fields:    Translation:Humans
    154. Flanagan CW, Parker JR, Mannel RS, Min KW, Kida M. Primary endodermal sinus tumor of the vulva: a case report and review of the literature. Gynecol Oncol. 1997 Sep; 66(3):515-8. PMID: 9299269.
      Citations: 4     Fields:    Translation:Humans
    155. Johnson GA, Mannel R, Khalifa M, Walker JL, Wren M, Min KW, Benbrook DM. Epidermal growth factor receptor in vulvar malignancies and its relationship to metastasis and patient survival. Gynecol Oncol. 1997 Jun; 65(3):425-9. PMID: 9190969.
      Citations: 14     Fields:    Translation:Humans
    156. Broun ER, Iseminger KA, Rose PG, Lentz SL, Malfetano JH, Lincoln S, Mannel R. A phase II trial of edatrexate in previously treated squamous cell cervical cancer: a Gynecologic Oncology Group study. Am J Clin Oncol. 1997 Feb; 20(1):78-80. PMID: 9020294.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    157. Khalifa MA, Abdoh AA, Mannel RS, Walker JL, Angros LH, Min KW. P-glycoprotein as a prognostic indicator in pre- and postchemotherapy ovarian adenocarcinoma. Int J Gynecol Pathol. 1997 Jan; 16(1):69-75. PMID: 8986535.
      Citations: 4     Fields:    Translation:Humans
    158. Khalifa MA, Lacher DA, Lage JM, Mannel RS, Walker JL, Angros LH, Min KW. Immunohistochemical assessment of proliferation markers and altered gene expression in archival specimens of ovarian epithelial tumors. Cancer Detect Prev. 1997; 21(6):532-9. PMID: 9398993.
      Citations: 1     Fields:    Translation:HumansAnimals
    159. Shen-Gunther J, Walker JL, Johnson GA, Mannel RS. Hepatic venoocclusive disease as a complication of whole abdominopelvic irradiation and treatment with the transjuglar intrahepatic portosystemic shunt: case report and literature review. Gynecol Oncol. 1996 May; 61(2):282-6. PMID: 8626148.
      Citations:    Fields:    Translation:Humans
    160. Mannel RS, Manetta A, Buller RE, Braly PS, Walker JL, Archer JS. Use of ileocecal continent urinary reservoir in patients with previous pelvic irradiation. Gynecol Oncol. 1995 Dec; 59(3):376-8. PMID: 8522258.
      Citations: 7     Fields:    Translation:Humans
    161. Flanagan CW, Mannel RS, Walker JL, Johnson GA. Incidence and location of para-aortic lymph node metastases in gynecologic malignancies. J Am Coll Surg. 1995 Jul; 181(1):72-4. PMID: 7599775.
      Citations:    Fields:    Translation:Humans
    162. Mannel RS, Manetta A, Hickman RL, Walker JL, Berman ML, DiSaia PJ. Cost analysis of Hickman catheter insertion at bedside in gynecologic oncology patients. J Am Coll Surg. 1994 Nov; 179(5):558-60. PMID: 7952458.
      Citations:    Fields:    Translation:Humans
    163. Khalifa MA, Mannel RS, Haraway SD, Walker J, Min KW. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Gynecol Oncol. 1994 Apr; 53(1):84-92. PMID: 7909788.
      Citations: 31     Fields:    Translation:Humans
    164. Khalifa MA, Abdoh AA, Mannel RS, Haraway SD, Walker JL, Min KW. Prognostic utility of epidermal growth factor receptor overexpression in endometrial adenocarcinoma. Cancer. 1994 Jan 15; 73(2):370-6. PMID: 8293402.
      Citations: 7     Fields:    Translation:Humans
    165. Shanbour KA, Mannel RS, Morris PC, Yadack A, Walker JL. Comparison of clinical versus surgical staging systems in vulvar cancer. Obstet Gynecol. 1992 Dec; 80(6):927-30. PMID: 1448261.
      Citations: 1     Fields:    Translation:Humans
    166. Chapman JA, Mannel RS, DiSaia PJ, Walker JL, Berman ML. Surgical treatment of unexpected invasive cervical cancer found at total hysterectomy. Obstet Gynecol. 1992 Dec; 80(6):931-4. PMID: 1448262.
      Citations: 2     Fields:    Translation:Humans
    167. Walker JL, Manetta A, Mannel RS. Hypogastric artery aneurysm masquerading as an ovarian neoplasm. Gynecol Oncol. 1992 Dec; 47(3):382-4. PMID: 1473753.
      Citations:    Fields:    Translation:Humans
    168. Bloss JD, DiSaia PJ, Mannel RS, Hyden EC, Manetta A, Walker JL, Berman ML. Radiation myelitis: a complication of concurrent cisplatin and 5-fluorouracil chemotherapy with extended field radiotherapy for carcinoma of the uterine cervix. Gynecol Oncol. 1991 Dec; 43(3):305-8. PMID: 1752503.
      Citations: 4     Fields:    Translation:Humans
    169. Walker JL, Manetta A, Mannel RS, Liao SY. Cellular fibroma masquerading as ovarian carcinoma. Obstet Gynecol. 1990 Sep; 76(3 Pt 2):530-1. PMID: 2381641.
      Citations: 3     Fields:    Translation:Humans
    170. Berman ML, Briggs GG, Bogh P, Mannel R, Manetta A, DiSaia PJ. Simplified postoperative patient-controlled analgesia on a gynecologic oncology service. Gynecol Oncol. 1990 Jul; 38(1):55-8. PMID: 1972368.
      Citations: 2     Fields:    Translation:Humans
    171. Mannel RS, Berman ML, Walker JL, Manetta A, DiSaia PJ. Management of endometrial cancer with suspected cervical involvement. Obstet Gynecol. 1990 Jun; 75(6):1016-22. PMID: 2342727.
      Citations: 3     Fields:    Translation:Humans
    172. Mannel RS, Braly PS, Buller RE. Indiana pouch continent urinary reservoir in patients with previous pelvic irradiation. Obstet Gynecol. 1990 May; 75(5):891-3. PMID: 2325973.
      Citations: 3     Fields:    Translation:HumansPHPublic Health
    173. Walker JL, Manetta A, Mannel RS, Berman ML, DiSaia PJ. The influence of endometriosis on the staging of cervical cancer. Obstet Gynecol. 1990 Mar; 75(3 Pt 2):543-5. PMID: 2304733.
      Citations: 1     Fields:    Translation:Humans
    174. Mannel RS, Stratton JA, Moran G, Rettenmaier MA, Liao SY, DiSaia PJ. Intraperitoneal cisplatin: comparison of antitumor activity and toxicity as a function of solvent saline concentration. Gynecol Oncol. 1989 Jul; 34(1):50-3. PMID: 2737526.
      Citations: 5     Fields:    Translation:Animals
    175. Stratton JA, Mannel RS, Rettenmaier MA, Berman ML, DiSaia PJ. Treatment of advanced and recurrent endometrial carcinoma: correlation of patient response to hormonal and cytotoxic chemotherapy and the response predicted by the subrenal capsule chemosensitivity assay. Gynecol Oncol. 1989 Jan; 32(1):55-9. PMID: 2535831.
      Citations:    Fields:    Translation:HumansAnimals
    176. Mannel RS, Stratton JA, Rettenmaier MA, Liao SY, DiSaia PJ. Use of a murine model for comparison of intravenous and intraperitoneal cisplatin in the treatment of microscopic ovarian cancer. Gynecol Oncol. 1988 Sep; 31(1):50-5. PMID: 3410355.
      Citations:    Fields:    Translation:Animals
    Mannel's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (477)
    Explore
    _
    Co-Authors (25)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _